Welcome to BioSeeker Group!

Antibodies in Oncology: Analytical Tool

Additional Information

Published Date Aug 22, 2016
Format Desktop App plus Online Access to Updates (One Year)
Publisher BioSeeker Group

Availability: In stock

$4,750.00

Quick Overview

This Analytical Tool transforms your computer’s desktop into a high capacity workbench within the area of antibodies in oncology. It supports you in making reports, presentations and preparing conference attendance and it is all done via an easy to use ’point and click’ interface.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Antibodies in Oncology: Analytical Tool.

    To find out more about Antibodies in Oncology: Analytical Tool, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Antibodies in Oncology: Analytical Tool is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals from a business development, drug development or investment perspective.

BioSeeker’s Analytical Tools have proven their worth to our clients in oncology for almost two decades in their capacities covering:

• Target Scouting
• Early & Late Stage Pipeline Analysis
• Biomarker/Companion Diagnostic Analysis
• Deal & Alliance Analysis
• Combination Therapy Analysis
• Indication Selection & Expansion Analysis
• First-in-Class Analysis
• Drug Repositioning
• Pipeline Analysis by Targeted Pathways

This Analytical Tool transforms your computer’s desktop into a high capacity workbench within the area of antibodies in oncology. Even before launching this desktop app you have already eliminated hundreds of hours of work needed to discover, process and piece together the thousands of sources that our team of oncology dedicated and highly experienced contents specialists have done on your behalf. It covers more than 542 companies plus partners who are today developing 2010 antibodies in oncology drugs where of 1308 are active in 3051 developmental projects in cancer across 416 different targets. The Analytical Tool and its contents are yours to keep and data can be easily exported into Excel format for mixing with your own proprietary information.

Let our expertise work for you

While executing some of your daily tasks in our Analytical Tools you will benefit from almost two decades of our experience in perfecting features and analysis, allowing you to easily create breakdowns, tables, graphs and exports for your reports, presentations and conference attendance via our easy to use point and click interface.

Support and inspiration at your finger-tips

You also have access to a great selection of How-to Training Videos showing best practice approaches to aspects such as competitive pipeline analysis right through to many real world case examples put forward by other users of our Analytical Tools.

A tool to grow with and keep you informed

Unlike a static report which just represents a particular snapshot in time, all of BioSeeker’s Analytical Tools come with one year of free online access to twice-weekly updates in both contents and features (valued at $2375), pipeline alerts and online support. You can choose to renew your access to these updates and support on a yearly basis or go completely online with our industry leading full service platform, 1stOncology.

Your key to accessing the 1stOncology Newsdesk

As a special bonus, your Analytical Tool unlocks lifetime* access to the 1stOncology Newdesk! This service, which is normally reserved for full 1stOncology users only, is a live stream of breaking news within the oncology industry. Updated every 5 minutes, you can tune in to specific channels such as Social Media, Clinical Trials, Intellectual Property, Financial data and Press Releases. This is a great tool to ensure your surveillance of your area of interest is complete.

Did you know?

BioSeeker’s Analytical Tools are a longstanding series of products powering decision making in oncology since 1999. Transform your computer’s desktop to a dedicated oncology workbench today! Request sample pages or order here to ensure you are not missing out on what you need to know.

System Requirements

- Operating system: Windows (2000/XP/Vista/7/10) for Desktop App and Mac OSX access only via our online service.
- Browser Application (Internet Explorer, FireFox, Chrome or Safari)
- Internet access (to access related internet resources)
(*) In this context, lifetime access refers to the full period of time that BioSeeker Group offer a Newsdesk product or similar news based service.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Antibodies in Oncology: Analytical Tool.
    To find out more about Antibodies in Oncology: Analytical Tool, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Antibodies in Oncology: Analytical Tool is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Analytical Tool' category:


Cancer Drugs with Biomarker Development: Analytical Tool
This Analytical Tool transforms your computer’s desktop into a high capacity workbench within the area of cancer drugs with biomarker development. It supports you in making reports, presentations and preparing conference attendance and it is all done via an easy to use ’point and click’ interface. Learn More


Orphan Drugs in Oncology: Analytical Tool
This Analytical Tool transforms your computer’s desktop into a high capacity workbench within the area of orphan drugs in oncology. It supports you in making reports, presentations and preparing conference attendance and it is all done via an easy to use ’point and click’ interface. Learn More

Other selected research from the 'Oncology' category:


Triple Analysis: Colorectal Cancer, Lymphoma and Pancreatic Cancer
This triple analysis focuses on cancer drug development strategies in Colorectal Cancer, Lymphoma and Pancreatic Cancer. Learn More


Triple Analysis: Breast Cancer, Pancreatic Cancer and Cancer Vaccines
This triple analysis focuses on cancer drug development strategies in both Breast Cancer and Pancreatic Cancer and by the mechanism/target/effect of Cancer Vaccines. Learn More

Other selected research from the 'Biologicals' category:


Cancer Vaccines: From First-in-Class to Best-in-Class?
In-depth pipeline analytics of cancer vaccine drugs showing you where the competition is, what is first-in-class and is first-in-class the best-in-class?, Indication expansion opportunities and much more Learn More


The Global Competitive Landscape of Antibody Drug Development in Cancer: The Faster Route to Consider Your Options and Position of Others
This report will excel your competitive awareness and decrease your decision making time in one of the fastest growing segments in the pharmaceutical market, namely antibodies for the treatment of cancer. Learn More

Other selected research from the 'Immunomodulators' category:


Cancer Vaccines Drug Pipeline Update
BioSeeker Group have identified 314 companies plus partners who are today developing 386 cancer vaccine drugs in 784 developmental projects in cancer across 195 different targets. In addition, there are 8 suspended drugs and another 208 drugs where development has been ceased. Learn More


Competitive Outlook on Non-Antibody Based Cancer Vaccines
Research and development in the cancer vaccine field is dominated by its top 10 players, interestingly not including any of the big pharma companies per se. The recent Gardasil approval and GlaxoSmithKline’s acquisition of Corixa will certainly push the industry towards more acquisitions. With this in mind, this report makes an in-depth assessment of competitive landscape, tumor antigen technologies, immunostimulatory strategies, vaccine delivery technologies, and a progress analysis of six major cancer vaccine indications. Learn More